Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Ocugen ( (OCGN) ) is now available.
On July 29, 2025, the U.S. District Court for the Eastern District of Pennsylvania granted Ocugen, Inc.’s motion to dismiss a securities class action lawsuit filed against the company and certain agents. The plaintiffs have 30 days to appeal, and Ocugen intends to continue its defense if an appeal is made.
The most recent analyst rating on (OCGN) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Ocugen stock, see the OCGN Stock Forecast page.
Spark’s Take on OCGN Stock
According to Spark, TipRanks’ AI Analyst, OCGN is a Neutral.
Ocugen’s overall score is driven primarily by its financial challenges, which are mitigated by positive technical trends and strategic corporate events. The optimistic earnings call and ongoing developments in gene therapy provide potential for future growth, but current financial instability and valuation concerns limit the overall score.
To see Spark’s full report on OCGN stock, click here.
More about Ocugen
Average Trading Volume: 5,723,761
Technical Sentiment Signal: Hold
Current Market Cap: $300.8M
See more insights into OCGN stock on TipRanks’ Stock Analysis page.